We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders

Andrew McKeon, MD1; Sean Pittock, MD1
[+] Author Affiliations
1Departments of Neurology and Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota
JAMA Neurol. 2013;70(9):1102-1104. doi:10.1001/jamaneurol.2013.3583.
Text Size: A A A
Published online


Neuromyelitis optica (NMO) spectrum disorders (NMOSDs) are inflammatory disorders of the central nervous system (CNS) characterized by attacks of optic neuritis or myelitis or both. The NMOSDs are the first inflammatory demyelinating diseases of the CNS for which a specific tissue target molecule has been identified: the astrocytic water channel aquaporin 4. They include NMO and limited NMO forms (predominantly occurring in patients who are seropositive for aquaporin 4–IgG and have had ≥1 attack of optic neuritis or myelitis only). The NMOSDs are now considered IgG-mediated autoimmune astrocytopathic diseases.1 The prognosis of untreated NMO is significantly worse than that of multiple sclerosis because recovery from attacks is usually incomplete, and incremental attack-related disability is more likely to develop. Early initiation of immunotherapy with successful prevention of attacks will probably have a greater effect on the natural history of NMO than on multiple sclerosis. The immunosuppressants most commonly prescribed for maintenance of remission, azathioprine or mycophenolate mofetil (with or without prednisone) and rituximab, have been assessed in small, uncontrolled studies only.26

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles